Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

We recently published a list of the 10 Best Long Term Stocks to Buy According to Billionaires. In this article, we are going ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

A new weight-loss pill taken daily could compete with injections like Ozempic, new research suggests. Patients, who all were ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.